The historical rank and industry rank for Frontier Biotechnologies's Pretax Margin % or its related term are showing as below:
SHSE:688221'
s Pretax Margin % Range Over the Past 10 Years
Min: -12938.04 Med: -463.08 Max: 0.88
Current: 0.88
SHSE:688221's Pretax Margin % is ranked worse than 65.38% of 956
companies
in the Drug Manufacturers industry
Industry Median: 7.285
vs SHSE:688221: 0.88
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Frontier Biotechnologies Pretax Margin % Related Terms
Frontier Biotechnologies Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688221 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Frontier Biotechnologies's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontier Biotechnologies Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Frontier Biotechnologies's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Frontier Biotechnologies's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Frontier Biotechnologies (SHSE:688221) has a Pretax Margin % of 76.53% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Frontier Biotechnologies and its competitors. According to the industry distribution chart, Frontier Biotechnologies ranks #625 out of 956 companies in the Drug Manufacturers industry, placing it in the top 65.4%.
Is Frontier Biotechnologies' Pretax Margin % too high?
Frontier Biotechnologies' current Pretax Margin % is 76.53%. The Drug Manufacturers industry median Pretax Margin % is 7.29. Frontier Biotechnologies' value of 76.53% is 950.5% above this industry median. Based on the distribution chart, Frontier Biotechnologies ranks #625 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Frontier Biotechnologies has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Frontier Biotechnologies' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Frontier Biotechnologies ranks #625 out of 956 companies for Pretax Margin %. This places Frontier Biotechnologies in the lower half of its industry. The industry median Pretax Margin % is 7.29. Frontier Biotechnologies' value of 76.53% is 950.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Frontier Biotechnologies's current Pretax Margin % of 76.53% is 950.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Frontier Biotechnologies and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Frontier Biotechnologies's current Pretax Margin % is 76.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontier Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Frontier Biotechnologies (SHSE:688221) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥37.31, compared to a current price of ¥27.60 — trading 26% below its estimated fair value. The current Pretax Margin % is 76.53% and 950.5% above the Drug Manufacturers industry median of 7.29. Frontier Biotechnologies' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Frontier Biotechnologies (SHSE:688221), the current Pretax Margin % is 76.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frontier Biotechnologies (SHSE:688221) Overvalued in 2026?
Based on GuruFocus' analysis, Frontier Biotechnologies stock appears to be undervalued.
The current stock price of ¥27.60 is trading 26% below its estimated GF Value™ of ¥37.31.
GuruFocus considers Frontier Biotechnologies to be Significantly Undervalued.
Key valuation signals for SHSE:688221:
Pretax Margin %: 76.53%
GF Value™: ¥37.31 vs. price of ¥27.60 (26% below fair value)
Industry Position: 950.5% above the Drug Manufacturers median (#625 of 956)
No single metric tells the full story. See the SHSE:688221 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688221 has been successfully added to your 
